HIV / AIDS

DOLPHIN-2 reports that dolutegravir is well-tolerated and achieves more rapid virological suppression prior to delivery compared to efavirenz when initiated during pregnancy.

Bacterial sexually transmitted infections are still prevalent among men who have sex with men in England, but PrEP and other measures have sharply cut the rate of new HIV diagnoses.

A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has been fighting HIV/AIDS since the 1980s when the virus was first discovered. Now, thanks to a joint effort by multiple arms of the US Department of Health and Human Services, he’s making headway.

Investigators from England report the longest adult HIV remission observed since the Berlin patient.

Over a 12-month study, there was a 13.9% increase of retention with viral load suppression among participants who received rapid viral load results following point-of-care testing.

Paul Sax, MD, explains how he would demystify PrEP to clinicians who are not comfortable using HIV medications.

W. David Hardy, MD, adjunct professor of medicine in the Division of Infectious Disease at Johns Hopkins University, talks about the challenges of treating patients with HIV and comorbidities.

Paul Sax, MD, explains the lack of concrete progress in the curing of HIV.

W. David Hardy, MD, discusses long-acting injectable agents in the pipeline.

Using genome sequencing, investigators have been able to identify clusters of individuals with HIV—with a particular focus on transgender women.

Women in the South look to family planning providers for more information about HIV PrEP, according a recent study in the journal Contraception.

Paul Edward Sax, MD, explains how one obstacle of HIV treatment and care is maintaining adherence.

W. David Hardy, MD, discusses the Undetectable Equals Untransmittable (U=U) movement.

A new assay distinguishes between intact and defective HIV proviruses in infected cells, a study reports.

Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.

Paul Sax, MD, discusses 2-drug approaches for treatment of HIV, including dolutegravir + lamivudine.

Ian Frank, MD discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Concerns of at-risk patients forgoing condoms may be driving the reluctance of some clinicians to prescribe the preventive regimen.

Paul Sax, MD, discusses treatments for HIV that are currently in development.

A new study finds that regular use of tenofovir gel helped reduce the risk of genital herpes acquisition in women in sub-Saharan Africa.

W. David Hardy, MD, discusses the challenges health care providers encounter when it comes to patients taking PrEP.

A shocking find on a CT scan leads to an unexpected diagnosis.

Ian Frank, MD, discusses strategies that individuals taking PrEP can use to maintain adherence to the daily regimen.

A breakthrough message for patients that must be delivered correctly by health care providers. The Undetectable Equals Untransmittable, or U=U, move­ment is a global campaign definitively stating that people living with HIV (PLWH) who have undetectable HIV RNA are unable to transmit HIV. By educating people, the hope is that they will get tested and, if necessary, start and stay on treatment. This message has been endorsed by many organizations, including the US Centers for Disease Control and Prevention and the HIV Medicine Association.

ART is associated with increased waist size in some people with HIV, and a new study aims to shed light on the factors involved.

The bold promise in last week’s State of the Union address is achievable, but may mean keeping the Affordable Care Act.

National Black HIV/AIDS Awareness Day is all about fighting the HIV stigma and encouraging education, testing, and prevention.

In an ongoing study spanning more than 15 years, investigators have made key discoveries about how HIV and TB drugs affect pregnant and postpartum women, leading to new safety and dosing recommendations for several medications.

In theory, investigators now have the tools to edit a patient’s genes to fight HIV. However, there’s a big difference between potential and reality.